4565.T
Nxera Pharma Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 1,180.00
+2.61%Sep 3, 2026, 07:10 UTC
Nexera Pharma announced it will receive a milestone payment of $8.6 million from Centessa Pharmaceuticals, a subsidiary of Eli Lilly, due to progress in late-stage development of an OX2R agonist.
Aug 26, 2026, 11:00 UTC
Neurocrine Biosciences' IND for NBI-1117567 Phase 2 trial in Alzheimer's cognitive impairment was accepted by the US FDA, triggering a $10 million milestone payment to Nexera Pharma.